BiomX Suspends Phase 2b Trial of BX004 for Cystic Fibrosis Due to Elevated Adverse Event Rates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: NASDAQ.COM
Discontinuation of Clinical Trial: BiomX Inc. has halted its Phase 2b clinical trial for BX004, a nebulized phage therapy for cystic fibrosis patients, due to high rates of adverse events and safety concerns raised by the Data Monitoring Committee.
FDA Hold and Protocol Adjustments: The FDA had previously placed a hold on U.S. enrollment for the trial, prompting the company to consider protocol adjustments, including revised dosing, which ultimately led to the decision to discontinue the program.
Shift in Focus: BiomX will now concentrate on advancing BX011, a phage cocktail targeting Staphylococcus aureus infections in diabetic foot infections, while implementing cost-cutting measures, including workforce reductions.
Stock Performance: Following the announcement, BiomX's stock price fell significantly, closing at $3.26, down nearly 37%, and has fluctuated between $2.92 and $22.05 over the past year.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PHGE with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PHGE
Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is 26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.580
Low
26.00
Averages
26.00
High
26.00
Current: 6.580
Low
26.00
Averages
26.00
High
26.00
About PHGE
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BiomX Shares Surge Following 19.99% Stake Acquisition
- Investor Acquisition: Pyu Pyu Capital's 13D filing reveals a 19.99% stake in BiomX, signaling potential active involvement in governance and strategic decisions, which could influence future shareholder votes.
- Stock Surge: BiomX shares surged 67.32% to $6.86 on Tuesday, reflecting market confidence in the new investor and the company's potential value, likely triggering further buying momentum in the short term.
- Market Reaction: The disclosure of a significant new holder often tightens trading float, amplifying price swings, particularly in biotech stocks where sentiment shifts can quickly translate into momentum-driven buying.
- Long-Term Challenges: Despite strong short-term performance, BiomX's stock has decreased by 54.53% over the past year and is closer to its 52-week lows, indicating ongoing challenges and uncertainties in the company's long-term growth trajectory.
Continue Reading
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
- Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
- Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
- Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
- Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.
Continue Reading